Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more
Fulcrum Therapeutics Inc (FULC) - Total Assets
Latest total assets as of September 2025: $214.86 Million USD
Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) holds total assets worth $214.86 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fulcrum Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fulcrum Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Fulcrum Therapeutics Inc's total assets of $214.86 Million consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.3% |
| Accounts Receivable | $3.34 Million | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fulcrum Therapeutics Inc's current assets represent 95.9% of total assets in 2024, an increase from 30.8% in 2017.
- Cash Position: Cash and equivalents constituted 22.3% of total assets in 2024, up from 9.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Fulcrum Therapeutics Inc Competitors by Total Assets
Key competitors of Fulcrum Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Fulcrum Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Fulcrum Therapeutics Inc generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Fulcrum Therapeutics Inc is currently not profitable relative to its asset base.
Fulcrum Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.70 | 18.44 | 4.23 |
| Quick Ratio | 17.70 | 18.44 | 4.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $194.23 Million | $ 252.98 Million | $ 86.19 Million |
Fulcrum Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Fulcrum Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.54 |
| Latest Market Cap to Assets Ratio | 0.92 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | $260.72 Million |
| Market Capitalization | $240.77 Million USD |
Valuation Analysis
Near Book Valuation: The market values Fulcrum Therapeutics Inc's assets close to their book value ( 0.92x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Fulcrum Therapeutics Inc's assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Fulcrum Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $260.72 Million | +1.17% |
| 2023-12-31 | $257.69 Million | +13.68% |
| 2022-12-31 | $226.69 Million | -3.54% |
| 2021-12-31 | $235.00 Million | +81.36% |
| 2020-12-31 | $129.58 Million | +17.33% |
| 2019-12-31 | $110.44 Million | +28.76% |
| 2018-12-31 | $85.77 Million | +1876.29% |
| 2017-12-31 | $4.34 Million | -- |